ꯁꯨꯗꯦꯁ (ꯆꯍꯤ ꯲꯳) ꯑꯁꯤ ꯅꯨꯃꯤꯠ ꯑꯗꯨꯗꯥ ꯌꯥꯝꯅꯥ ꯋꯥꯅꯥ ꯑꯩꯒꯤ ꯀ꯭ꯂꯤꯅꯤꯀꯇꯥ ꯂꯥꯀꯈꯤ꯫ ꯃꯍꯥꯛꯅꯥ ꯍꯟꯗꯛꯇꯥ ꯏꯟꯇꯔꯅꯦꯠꯇꯥ ꯄꯥꯈꯤ ꯃꯗꯨꯗꯤ ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯗꯥ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤ ꯃꯔꯛꯇꯥ HIV (ꯍ꯭ꯌꯨꯃꯦꯟ ꯏꯝꯝꯌꯨꯅꯣꯗꯦꯐꯤꯁꯤꯑꯦꯟꯁꯤ ꯚꯥꯏꯔꯁ) ꯏꯅꯐꯦꯛꯁꯟ ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯊꯨꯅꯥ ꯍꯦꯅꯒꯠꯂꯛꯂꯤ꯫
"ꯗꯥꯛꯇꯔ ꯄ꯭ꯔꯤꯌꯥ, ꯑꯩꯍꯥꯛꯅꯥ ꯗꯦꯇꯥ ꯑꯁꯤ ꯎꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯂꯥꯡꯇꯛꯅꯩ꯫ ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯒꯤ ꯐꯤꯚꯝ ꯑꯁꯤ ꯇꯁꯦꯡꯅꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯐꯠꯇꯕꯥ ꯑꯣꯏꯕꯔꯥ? ꯃꯔꯨꯑꯣꯏꯅꯥ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯅꯨꯄꯥꯁꯤꯡꯒꯤ ꯃꯔꯛꯇꯥ ꯁꯟꯗꯣꯔꯀꯄꯒꯤ ꯃꯔꯝ ꯀꯔꯤꯅꯣ? ꯑꯩꯈꯣꯌꯅꯥ ꯃꯁꯤꯗꯒꯤ ꯅꯥꯟꯊꯣꯀꯄꯥ ꯉꯃꯒꯗ꯭ꯔꯥ?" ꯁꯨꯗꯦꯁꯅꯥ ꯌꯥꯝꯅꯥ ꯅꯨꯡꯉꯥꯏꯅꯥ ꯍꯪꯈꯤ꯫
ꯑꯩꯅꯥ ꯅꯤꯡꯊꯤꯖꯅꯥ ꯁꯨꯗꯦꯁꯇꯥ ꯐꯣꯡꯗꯣꯀꯈꯤ: "ꯁꯨꯗꯦꯁ, ꯅꯍꯥꯛꯅꯥ ꯋꯥꯍꯪ ꯑꯁꯤ ꯍꯪꯕꯁꯤ ꯌꯥꯝꯅꯥ ꯃꯔꯨꯑꯣꯏ꯫ ꯃꯔꯃꯗꯤ ꯉꯁꯤꯗꯤ ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯗꯥ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯃꯤꯔꯣꯂꯁꯤꯡꯒꯤ ꯃꯔꯛꯇꯥ ꯑꯩꯆ.ꯑꯥꯏ.ꯚꯤ.
ꯗꯦꯇꯥ ꯑꯁꯤꯅꯥ ꯍꯥꯌꯔꯤ: ꯀꯔꯤꯒꯤꯗꯃꯛꯇꯥ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯅꯨꯄꯥꯁꯤꯡꯗꯥ HIV ꯍꯦꯅꯒꯠꯂꯛꯂꯤꯕꯅꯣ?
ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯩꯈꯣꯌꯅꯥ ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯒꯤ ꯅꯦꯁ꯭ꯅꯦꯜ ꯁꯦꯛꯁꯨꯑꯦꯂꯤ ꯇ꯭ꯔꯥꯟꯁꯃꯤꯇꯦꯗ ꯗꯤꯖꯤꯖ ꯑꯃꯁꯨꯡ ꯑꯦꯗꯁ ꯀꯟꯠꯔꯣꯜ ꯄ꯭ꯔꯣꯒ꯭ꯔꯥꯃꯒꯤ ꯗꯦꯇꯥ ꯌꯦꯡꯂꯕꯗꯤ, ꯍꯟꯗꯛꯀꯤ ꯃꯇꯝ ꯑꯁꯤꯗꯥ ꯅꯧꯅꯥ ꯔꯤꯄꯣꯔꯠ ꯇꯧꯔꯀꯄꯥ HIV ꯏꯅꯐꯦꯛꯁꯅꯒꯤ ꯃꯁꯤꯡ ꯌꯥꯝꯂꯕꯥ ꯃꯁꯤꯡ ꯑꯁꯤ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯅꯨꯄꯥꯁꯤꯡꯅꯤ ꯍꯥꯌꯅꯥ ꯎꯕꯥ ꯐꯪꯏ꯫
2022ꯗꯥ ꯔꯤꯄꯣꯔꯠ ꯇꯧꯔꯀꯄꯥ ꯗꯦꯇꯥꯒꯤ ꯃꯇꯨꯡꯏꯟꯅꯥ, ꯆꯍꯤ 15-24 ꯐꯥꯎꯕꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯂꯩꯕꯥ ꯅꯍꯥꯁꯤꯡꯅꯥ HIV ꯏꯅꯐꯦꯛꯁꯟ ꯄꯨꯝꯅꯃꯛꯀꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 12% ꯑꯣꯏꯔꯤ꯫ ꯃꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯹꯲%ꯗꯤ ꯅꯍꯥ ꯑꯣꯏꯔꯤꯕꯥ ꯅꯨꯄꯥꯁꯤꯡꯅꯤ, ꯑꯃꯁꯨꯡ ꯃꯈꯣꯌꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯸꯰%ꯗꯤ ꯅꯨꯄꯥꯁꯤꯡꯒꯥ ꯉꯥꯀꯊꯣꯛꯂꯣꯏꯗꯕꯥ ꯁꯦꯛꯁ ꯇꯧꯈꯤ ꯍꯥꯌꯅꯥ ꯔꯤꯄꯣꯔꯠ ꯇꯧꯔꯀꯈꯤ꯫
ꯋꯦꯁ꯭ꯇꯔꯟ ꯑꯃꯁꯨꯡ ꯅꯣꯔꯊ-ꯋꯦꯁ꯭ꯇꯔꯟ ꯄ꯭ꯔꯣꯕꯤꯟꯁꯁꯤꯡꯒꯤ ꯀꯣꯂꯝꯕꯣ, ꯒꯝꯄꯥꯍꯥ, ꯀꯥꯂꯨꯇꯥꯔꯥ ꯑꯃꯁꯨꯡ ꯀꯨꯔꯨꯅꯦꯒꯥꯂꯥ ꯖꯤꯂꯥꯁꯤꯡꯗꯒꯤ, ꯑꯃꯁꯨꯡ ꯈꯥ ꯊꯪꯕꯥ ꯄ꯭ꯔꯣꯕꯤꯟꯁꯀꯤ ꯒꯥꯜꯂꯦ ꯖꯤꯂꯥꯗꯒꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯌꯥꯝꯅꯥ HIV ꯏꯅꯐꯦꯛꯁꯟ ꯂꯩꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡ ꯔꯤꯄꯣꯔꯠ ꯇꯧꯔꯀꯈꯤ꯫ ꯃꯤꯑꯣꯏ ꯀꯌꯥꯅꯥ ꯃꯇꯝ ꯁꯥꯡꯅꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯂꯩꯔꯦ ꯍꯥꯌꯕꯥ ꯈꯉꯕꯈꯛꯇꯅꯤ꯫ ꯃꯇꯝ ꯑꯗꯨꯗꯥ ꯃꯈꯣꯌꯒꯤ ꯁꯤ.ꯗꯤ.꯴ ꯀꯥꯎꯟꯇ (ꯏꯝꯌꯨꯟ ꯁꯦꯂꯒꯤ ꯃꯁꯤꯡ) ꯑꯁꯤ ꯌꯥꯝꯅꯥ ꯅꯦꯝꯃꯤ꯫ ꯃꯁꯤꯅꯥ ꯇꯥꯛꯂꯤ ꯃꯗꯨꯗꯤ ꯃꯈꯣꯌꯅꯥ ꯂꯥꯌꯅꯥ ꯑꯁꯤ ꯉꯟꯅꯥ ꯇꯦꯁ꯭ꯠ ꯇꯧꯕꯒꯤ ꯊꯧꯑꯣꯡ ꯄꯥꯉꯊꯣꯀꯈꯤꯗ꯭ꯔꯤ꯫
ꯀꯔꯤꯒꯤꯗꯃꯛꯇꯥ ꯅꯨꯄꯥꯒꯤ ꯍꯣꯃꯣꯁꯦꯛꯁꯨꯑꯦꯜ ꯔꯤꯂꯦꯁꯅꯁꯤꯞ ꯑꯁꯤꯅꯥ HIV ꯁꯟꯗꯣꯀꯄꯒꯤ ꯔꯤꯁ꯭ꯛ ꯍꯦꯟꯅꯥ ꯊꯣꯀꯍꯜꯂꯤꯕꯅꯣ?
ꯅꯨꯄꯥꯁꯤꯡꯒꯥ ꯁꯦꯛꯁ ꯇꯧꯔꯤꯕꯥ ꯅꯨꯄꯥꯁꯤꯡꯗꯥ HIV ꯇ꯭ꯔꯥꯟꯁꯃꯤꯁꯅꯒꯤ ꯔꯤꯁ꯭ꯛ ꯍꯦꯅꯒꯠꯂꯀꯄꯗꯥ ꯃꯔꯨꯑꯣꯏꯕꯥ ꯃꯔꯝ ꯀꯌꯥꯅꯥ ꯃꯇꯦꯡ ꯄꯥꯡꯂꯤ (MSM) :
1. ꯕꯥꯏꯑꯣꯂꯣꯖꯤꯀꯦꯜ ꯔꯤꯁ꯭ꯛ: ꯑꯦꯅꯥꯜ ꯁꯦꯛꯁꯀꯤ ꯃꯇꯃꯗꯥ, ꯈꯣꯡꯗꯥ ꯂꯩꯔꯤꯕꯥ ꯁ꯭ꯃꯨꯗ ꯇꯤꯁꯨꯁꯤꯡ ꯑꯁꯤ ꯐꯖꯅꯥ ꯑꯁꯣꯛ-ꯑꯄꯟ ꯅꯠꯠꯔꯒꯥ ꯁꯣꯀꯄꯥ ꯌꯥꯏ, ꯃꯗꯨꯅꯥ ꯁꯦꯛꯁꯨꯑꯦꯜ ꯐ꯭ꯂꯨꯏꯗꯇꯥ ꯂꯩꯕꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯏꯒꯤ ꯈꯣꯡꯖꯦꯂꯗꯥ ꯍꯀꯊꯦꯡꯅꯅꯥ ꯍꯀꯆꯥꯡꯗꯥ ꯆꯪꯕꯗꯥ ꯂꯥꯌꯍꯜꯂꯤ꯫
2. ꯀꯟꯗꯣꯝ ꯁꯤꯖꯤꯟꯅꯕꯥ ꯅꯦꯝꯕꯥ: ꯇꯣꯉꯥꯟ-ꯇꯣꯉꯥꯅꯕꯥ ꯁꯔꯚꯦꯁꯤꯡꯅꯥ ꯇꯥꯛꯂꯤꯕꯒꯨꯝꯅꯥ, ꯁꯦꯛꯁꯀꯤ ꯃꯔꯤ ꯂꯩꯅꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯌꯥꯝꯅꯥ ꯅꯦꯝꯕꯥ (ꯆꯥꯎꯔꯥꯛꯅꯥ 18%) ꯈꯛꯇꯅꯥ ꯃꯈꯣꯌꯒꯤ ꯑꯔꯣꯏꯕꯥ ꯁꯦꯛꯁꯨꯑꯦꯜ ꯏꯟꯇꯔꯀꯣꯔꯁꯀꯤ ꯃꯇꯃꯗꯥ ꯀꯟꯗꯣꯝ ꯑꯁꯤ ꯃꯑꯣꯡ ꯆꯨꯝꯅꯥ ꯁꯤꯖꯤꯟꯅꯈꯤ꯫
3. ꯁꯣꯁꯤꯑꯦꯜ ꯁ꯭ꯇꯤꯒꯃꯥ: ꯁꯣꯁꯤꯑꯦꯜ ꯁ꯭ꯇꯤꯒꯃꯥ ꯑꯃꯁꯨꯡ ꯑꯥꯏꯅꯒꯤ ꯑꯣꯏꯕꯥ ꯑꯊꯤꯡꯕꯁꯤꯡꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯃꯤꯑꯣꯏ ꯀꯌꯥꯅꯥ ꯃꯈꯣꯌꯒꯤ ꯁꯦꯛꯁꯨꯑꯦꯜ ꯑꯥꯏꯗꯦꯟꯇꯤꯇꯤ ꯂꯣꯠꯁꯤꯜꯂꯤ꯫ ꯃꯁꯤꯅꯥ ꯃꯈꯣꯌꯗꯥ ꯍꯦꯂꯊ ꯀ꯭ꯂꯤꯅꯤꯀꯁꯤꯡꯗꯥ ꯆꯠꯇꯨꯅꯥ HIV ꯇꯦꯁ꯭ꯠ ꯇꯧꯕꯗꯥ ꯌꯥꯝꯅꯥ ꯋꯥꯅꯥ ꯊꯣꯀꯍꯜꯂꯤ꯫
🚨 ꯈꯨꯗꯛꯇꯥ ꯃꯦꯗꯤꯀꯦꯂꯒꯤ ꯃꯇꯦꯡ ꯃꯊꯧ ꯇꯥꯕꯥ ꯔꯦꯗ ꯐ꯭ꯂꯦꯒꯁꯤꯡ꯫
ꯃꯈꯥꯗꯥ ꯄꯤꯔꯤꯕꯥ ꯂꯥꯏꯑꯣꯡꯁꯤꯡ ꯑꯁꯤ HIV ꯚꯥꯏꯔꯁꯅꯥ ꯍꯀꯆꯥꯡꯗꯥ ꯆꯪꯂꯕꯥ ꯃꯇꯨꯡ ꯅꯨꯃꯤꯠ 2 ꯑꯃꯁꯨꯡ 6ꯒꯤ ꯃꯔꯛꯇꯥ (ꯁꯦꯔꯣꯀꯅꯕꯔꯁꯟ ꯂꯥꯌꯅꯥꯒꯤ ꯃꯇꯃꯗꯥ) ꯂꯥꯀꯄꯥ ꯌꯥꯏ, ꯑꯃꯁꯨꯡ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯁꯤꯒꯨꯝꯕꯥ ꯑꯀꯤꯕꯥ ꯄꯣꯀꯍꯅꯕꯥ ꯌꯥꯕꯥ ꯀꯟꯇꯦꯛꯇꯀꯤ ꯃꯇꯨꯡꯗꯥ ꯂꯥꯀꯄꯥ ꯑꯣꯏꯔꯕꯗꯤ, ꯅꯍꯥꯛꯅꯥ ꯈꯨꯗꯛꯇꯥ ꯃꯦꯗꯤꯀꯦꯜ ꯀ꯭ꯂꯤꯅꯤꯛ ꯑꯃꯗꯥ ꯆꯠꯀꯗꯕꯅꯤ:
- ꯂꯦꯡ-ꯑꯣꯠꯄꯒꯤ ꯆꯥꯡ ꯋꯥꯡꯈꯠꯄꯥ ꯑꯃꯁꯨꯡ ꯅꯨꯃꯤꯗꯥꯡꯒꯤ ꯃꯇꯃꯗꯥ ꯌꯥꯝꯅꯥ ꯋꯥꯅꯥ ꯊꯣꯀꯄꯥ꯫
- ꯃꯔꯝ ꯑꯃꯠꯇꯥ ꯂꯩꯇꯅꯥ ꯑꯇꯦꯅꯕꯥ ꯃꯇꯃꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯍꯀꯆꯥꯡꯒꯤ ꯑꯔꯨꯝꯕꯥ ꯌꯥꯝꯅꯥ ꯊꯨꯅꯥ ꯍꯟꯊꯔꯀꯄꯥ (Unexplained Weight Loss)꯫
- ꯅꯨꯃꯤꯠ ꯀꯌꯥꯅꯤꯒꯤ ꯑꯣꯏꯅꯥ ꯈꯣꯡ, ꯈꯣꯡꯄꯥꯛ ꯅꯠꯠꯔꯒꯥ ꯈꯣꯡꯗꯥ ꯂꯤꯝꯐ ꯅꯣꯗꯁꯤꯡ ꯁꯣꯟꯊꯕꯥ꯫
- ꯃꯇꯝ ꯁꯥꯡꯅꯥ ꯗꯥꯏꯔꯤꯌꯥ ꯑꯃꯁꯨꯡ ꯅꯟ-ꯍꯤꯂꯤꯡ ꯃꯤꯠ ꯁꯣꯟꯊꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯐꯉ꯭ꯒꯦꯜ ꯏꯅꯐꯦꯛꯁꯅꯁꯤꯡ꯫
HIV ꯁꯟꯗꯣꯔꯀꯄꯥ ꯑꯁꯤ ꯀꯔꯝꯅꯥ ꯊꯤꯡꯒꯗꯒꯦ? (ꯄ꯭ꯔꯤꯚꯦꯟꯁꯟ) ꯑꯃꯁꯨꯡ ꯑꯦꯟ.
ꯅꯨꯡꯉꯥꯏꯕꯥ ꯄꯥꯎ ꯑꯃꯗꯤ ꯑꯐꯕꯥ ꯍꯀꯁꯦꯂꯒꯤ ꯂꯃꯆꯠ-ꯁꯥꯖꯠꯁꯤꯡ ꯉꯥꯛꯅꯥ ꯆꯠꯄꯅꯥ HIV ꯂꯧꯅꯕꯒꯤ ꯔꯤꯁ꯭ꯛ ꯑꯁꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ ꯃꯄꯨꯡꯐꯥꯅꯥ ꯂꯧꯊꯣꯀꯄꯥ ꯉꯝꯃꯤ:
- ꯑꯆꯨꯝꯕꯥ ꯀꯟꯗꯣꯝ ꯁꯤꯖꯤꯟꯅꯕꯥ: ꯅꯍꯥꯛꯅꯥ ꯁꯦꯛꯁ ꯇꯧꯕꯥ ꯈꯨꯗꯤꯡꯗꯥ ꯕꯔꯊ ꯀꯟꯠꯔꯣꯜ ꯀꯟꯗꯣꯃꯁꯤꯡ ꯑꯆꯨꯝꯕꯥ ꯃꯑꯣꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯕꯅꯥ HIV ꯇ꯭ꯔꯥꯟꯁꯃꯤꯁꯟ ꯑꯁꯤ 90%ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯊꯤꯡꯕꯥ ꯉꯝꯃꯤ꯫
- PrEP (ꯄ꯭ꯔꯤ-ꯑꯦꯛꯁꯄꯣꯖꯔ ꯄ꯭ꯔꯣꯐꯥꯏꯂꯦꯛꯁꯤꯁ) ꯁꯤꯖꯤꯟꯅꯕꯥ: ꯃꯁꯤꯕꯨ ꯄ꯭ꯔꯤ-ꯑꯦꯛꯁꯄꯣꯖꯔ ꯄ꯭ꯔꯣꯐꯥꯏꯂꯦꯛꯁꯤꯁ ꯍꯥꯌꯅꯥ ꯀꯧꯏ꯫ HIV ꯏꯅꯐꯦꯛꯁꯅꯒꯤ ꯔꯤꯁ꯭ꯛ ꯋꯥꯡꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯅꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯊꯀꯄꯥ ꯍꯤꯗꯥꯛ ꯑꯁꯤꯅꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯂꯧꯅꯕꯒꯤ ꯔꯤꯁ꯭ꯛ ꯑꯁꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 99% ꯊꯤꯡꯏ꯫
- ꯆꯥꯡ ꯅꯥꯏꯅꯥ ꯇꯦꯁ꯭ꯠ ꯇꯧꯕꯥ: ꯁꯦꯛꯁꯨꯑꯦꯜꯂꯤ ꯑꯦꯛꯇꯤꯚ ꯑꯣꯏꯕꯥ ꯃꯤꯑꯣꯏ ꯑꯃꯅꯥ ꯆꯍꯤ ꯑꯃꯗꯥ ꯌꯥꯃꯗ꯭ꯔꯕꯗꯥ ꯑꯃꯨꯛ ꯍꯟꯅꯥ HIV ꯇꯦꯁ꯭ꯠ ꯇꯧꯒꯗꯕꯅꯤ꯫ ꯍꯧꯖꯤꯛꯀꯤ ꯑꯣꯏꯅꯥ ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯗꯥ ꯅꯥꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤ ꯸꯶%ꯅꯥ ꯃꯈꯣꯌꯗꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯂꯩꯔꯦ ꯍꯥꯌꯕꯥ ꯈꯉꯏ, ꯑꯃꯁꯨꯡ ꯌꯨ.ꯑꯦꯟ.ꯑꯦ.ꯑꯥꯏ.ꯗꯤ.ꯗꯤ.(ꯖꯣꯏꯟꯇ ꯌꯨꯅꯥꯏꯇꯦꯗ ꯅꯦꯁꯟꯁ ꯄ꯭ꯔꯣꯒ꯭ꯔꯥꯝ ꯑꯣꯟ ꯑꯦꯗꯁ) ꯅꯥ ꯃꯁꯤ ꯹꯵%ꯗꯥ ꯍꯦꯅꯒꯠꯍꯟꯅꯕꯥ ꯄꯥꯟꯗꯝ ꯊꯝꯂꯤ꯫
- ꯄꯤ.ꯏ.ꯄꯤ.(Post-Exposure Prophylaxis) ꯁꯤꯖꯤꯟꯅꯕꯥ: ꯀꯔꯤꯒꯨꯝꯕꯥ ꯄ꯭ꯔꯣꯇꯦꯛꯇꯦꯗ ꯁꯦꯛꯁ ꯑꯃꯥ ꯊꯣꯛꯂꯕꯗꯤ, ꯄꯨꯡ 72ꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯂꯧꯕꯥ ꯑꯦꯃꯔꯖꯦꯟꯁꯤ ꯂꯥꯏꯌꯦꯡ ꯑꯁꯤꯅꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯁꯟꯗꯣꯀꯄꯥ ꯊꯤꯡꯕꯥ ꯉꯝꯃꯤ꯫
ꯂꯥꯏꯌꯦꯡ: HIVꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯍꯀꯆꯥꯡ ꯐꯅꯥ ꯂꯩꯕꯥ꯫
ꯃꯃꯥꯡꯗꯥ HIV ꯑꯁꯤ ꯁꯤꯍꯅꯕꯥ ꯌꯥꯕꯥ ꯂꯥꯌꯅꯥ ꯑꯃꯥ ꯑꯣꯏꯅꯥ ꯂꯧꯅꯔꯕꯁꯨ, ꯃꯣꯗꯔꯟ ꯃꯦꯗꯤꯀꯦꯜ ꯇ꯭ꯔꯤꯠꯃꯦꯟꯇꯁꯤꯡꯅꯥ ꯑꯅꯥꯕꯁꯤꯡꯕꯨ ꯅꯣꯔꯃꯦꯜ ꯑꯣꯏꯕꯥ ꯍꯀꯆꯥꯡ ꯐꯕꯥ ꯃꯤꯑꯣꯏ ꯑꯃꯒꯥ ꯃꯥꯟꯅꯅꯥ ꯍꯤꯡꯕꯥ ꯉꯃꯍꯜꯂꯦ꯫
ꯃꯔꯨꯑꯣꯏꯕꯥ ꯂꯥꯏꯌꯦꯡ ꯑꯁꯤ ART (Antiretroviral Therapy) . ꯍꯥꯌꯔꯤꯕꯥ ꯗ꯭ꯔꯒꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯍꯀꯆꯥꯡꯗꯥ ꯚꯥꯏꯔꯁ ꯃꯁꯤꯡ ꯌꯥꯝꯅꯥ ꯍꯦꯅꯒꯠꯂꯀꯄꯥ ꯑꯁꯤ ꯃꯄꯨꯡ ꯐꯥꯅꯥ ꯀꯟꯠꯔꯣꯜ ꯇꯧꯏ꯫
ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯗꯥ HIVꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯍꯤꯡꯂꯤꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯒꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ 80%ꯗꯤ ꯍꯧꯖꯤꯛ ART ꯂꯧꯔꯤ, ꯑꯃꯁꯨꯡ ꯃꯈꯣꯌꯒꯤ ꯃꯅꯨꯡꯗꯥ 87%ꯗꯤ ꯈꯪꯗꯣꯀꯄꯥ ꯉꯃꯗꯕꯥ ꯚꯥꯏꯔꯁ ꯂꯣꯗ ꯂꯩ꯫ ꯚꯥꯏꯔꯁ ꯂꯣꯗ ꯑꯁꯤ ꯕ꯭ꯂꯗ ꯇꯦꯁ꯭ꯠ ꯑꯃꯗꯥ ꯐꯥꯎꯕꯥ ꯈꯪꯗꯣꯀꯄꯥ ꯉꯃꯗꯕꯥ ꯊꯥꯛ ꯑꯃꯗꯥ ꯀꯟꯠꯔꯣꯜ ꯇꯧꯕꯥ ꯃꯇꯃꯗꯥ (Undetectable = Untransmittable) ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯑꯇꯣꯞꯄꯥ ꯃꯤꯑꯣꯏ ꯑꯃꯗꯥ ꯁꯟꯗꯣꯀꯄꯒꯤ ꯔꯤꯁ꯭ꯛ ꯑꯁꯤ ꯖꯤꯔꯣ (0%)ꯗꯥ ꯍꯟꯊꯔꯀꯏ꯫
ꯇꯧꯒꯗꯕꯥ ꯑꯃꯁꯨꯡ ꯇꯧꯔꯣꯏꯗꯕꯅꯤ꯫
| ✔️ ꯇꯧꯒꯗꯕꯥ ꯊꯕꯀꯁꯤꯡ (ꯀꯔꯤ ꯇꯧꯕꯥ) | ❌ ꯇꯧꯔꯣꯏꯗꯕꯅꯤ꯫ |
|---|---|
| ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯁꯦꯛꯁꯨꯑꯦꯜꯂꯤ ꯑꯦꯛꯇꯤꯚ ꯑꯣꯏꯔꯕꯗꯤ, ꯁꯔꯀꯥꯔꯒꯤ ꯁꯦꯛꯁ ꯀ꯭ꯂꯤꯅꯤꯛ ꯑꯃꯗꯥ ꯅꯠꯠꯔꯒꯥ ꯊꯥꯖꯕꯥ ꯌꯥꯕꯥ ꯄ꯭ꯔꯥꯏꯚꯦꯠ ꯀ꯭ꯂꯤꯅꯤꯛ ꯑꯃꯗꯥ ꯆꯠꯂꯨ ꯑꯃꯁꯨꯡ ꯒꯣꯄꯟ ꯑꯣꯏꯕꯥ HIV ꯇꯦꯁ꯭ꯠ ꯑꯃꯥ ꯇꯧ꯫ | ꯂꯥꯏꯑꯣꯡꯁꯤꯡ ꯎꯕꯥ ꯐꯪꯂꯕꯁꯨ, ꯈꯨꯟꯅꯥꯏꯒꯤ ꯑꯣꯏꯕꯥ ꯋꯥꯈꯜꯂꯣꯅꯁꯤꯡꯗꯥ ꯑꯀꯤꯕꯥ ꯂꯩꯕꯅꯥ ꯃꯦꯗꯤꯀꯦꯜ ꯀ꯭ꯂꯤꯅꯤꯀꯁꯤꯡꯗꯥ ꯆꯠꯍꯟꯗꯅꯥ ꯅꯍꯥꯛꯀꯤ ꯑꯅꯥꯕꯥ ꯑꯗꯨ ꯂꯣꯠꯁꯤꯅꯒꯅꯨ꯫ |
| ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯔꯤꯁ꯭ꯛ ꯋꯥꯡꯕꯥ ꯀꯥꯡꯂꯨꯞ ꯑꯃꯗꯥ ꯂꯩꯔꯕꯗꯤ, ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯇꯥꯀꯄꯥ ꯃꯇꯨꯡꯏꯟꯅꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ PrEP ꯁꯤꯖꯤꯟꯅꯧ꯫ | ꯁꯤꯔꯤꯟꯖꯁꯤꯡ ꯁꯦꯌꯔ ꯇꯧꯔꯣꯏꯗꯕꯅꯤ (ꯃꯁꯤ ꯗ꯭ꯔꯒ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯁꯤꯡꯒꯤ ꯃꯔꯛꯇꯥ ꯀꯃꯟ ꯑꯣꯏ)꯫ |
| ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛ ꯑꯁꯤ HIV ꯄꯣꯖꯤꯇꯤꯚ ꯑꯣꯏꯔꯕꯗꯤ, ꯅꯍꯥꯛꯀꯤ ꯗꯣꯛꯇꯔꯅꯥ ꯄꯤꯕꯥ ART ꯍꯤꯗꯥꯀꯁꯤꯡ ꯑꯗꯨ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯂꯦꯄꯊꯣꯛꯂꯕꯥ ꯃꯇꯃꯗꯥ ꯂꯧꯊꯣꯀꯎ꯫ | HIVꯅꯥ ꯅꯥꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯕꯨ ꯌꯦꯛꯅꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯈꯦꯟꯅꯕꯥ ꯊꯃꯗꯅꯥ ꯌꯦꯡꯕꯤꯒꯅꯨ꯫ |
❓ ꯑꯗꯣꯃꯗꯥ ꯍꯪꯂꯀꯄꯥ ꯌꯥꯕꯥ ꯑꯇꯣꯞꯄꯥ ꯋꯥꯍꯪ ꯈꯔꯥ (FAQ)
ꯁ꯭ꯔꯤꯂꯉ꯭ꯀꯥꯗꯥ ꯐ꯭ꯔꯤ ꯑꯣꯏꯅꯥ HIV ꯇꯦꯁ꯭ꯠ ꯀꯗꯥꯏꯗꯥ ꯐꯪꯒꯗꯒꯦ? ▼
HIV ꯇꯦꯁ꯭ꯠ ꯇꯧꯕꯥ ꯑꯁꯤ ꯑꯥꯏꯂꯦꯟꯗ ꯁꯤꯅꯕꯥ ꯊꯨꯡꯅꯥ ꯂꯩꯔꯤꯕꯥ ꯁꯔꯀꯥꯔꯒꯤ ꯑꯦꯁ.ꯇꯤ.ꯗꯤ.ꯒꯤ ꯀ꯭ꯂꯤꯅꯤꯛ ꯑꯃꯍꯦꯛꯇꯗꯥ, ꯃꯃꯜ ꯇꯤꯡꯗꯅꯥ, ꯃꯄꯨꯡ ꯐꯥꯅꯥ ꯒꯣꯄꯟ ꯑꯣꯏꯅꯥ ꯄꯥꯡꯊꯣꯀꯄꯥ ꯌꯥꯏ꯫
PrEP ꯁꯤꯖꯤꯟꯅꯕꯅꯥ ꯑꯇꯩ ꯁꯦꯛꯁꯨꯑꯦꯜꯂꯤ ꯇ꯭ꯔꯥꯟꯁꯃꯤꯇꯦꯗ ꯏꯅꯐꯦꯛꯁꯅꯁꯤꯡ (STIs) ꯊꯤꯡꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ? ▼
ꯅꯠꯇꯦ, PrEP ꯑꯁꯤꯅꯥ HIV ꯏꯅꯐꯦꯛꯁꯟ ꯈꯛꯇꯃꯛ ꯊꯤꯡꯏ꯫ ꯀꯟꯗꯣꯃꯁꯤꯡ ꯑꯁꯤ ꯑꯇꯩ ꯁꯦꯛꯁꯨꯑꯦꯜꯂꯤ ꯇ꯭ꯔꯥꯟꯁꯃꯤꯇꯦꯗ ꯂꯥꯌꯅꯥꯁꯤꯡ, ꯍꯥꯌꯕꯗꯤ ꯁꯤꯐꯤꯂꯤꯁ, ꯒꯣꯅꯣꯔꯤꯌꯥ ꯅꯠꯠꯔꯒꯥ ꯍꯔꯄꯤꯁ ꯑꯁꯤꯅꯆꯤꯡꯕꯗꯒꯤ ꯉꯥꯀꯊꯣꯛꯅꯕꯥ ꯁꯤꯖꯤꯟꯅꯒꯗꯕꯅꯤ꯫
ꯃꯃꯥ ꯑꯃꯗꯒꯤ ꯃꯍꯥꯛꯀꯤ ꯑꯉꯥꯡꯗꯥ HIV ꯁꯟꯗꯣꯀꯄꯥ ꯊꯤꯡꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ? ▼
ꯍꯣꯌ, ꯃꯃꯥꯗꯥ ꯃꯤꯔꯣꯜꯂꯤꯉꯩ ꯃꯇꯃꯗꯥ ꯃꯇꯤꯛ ꯆꯥꯕꯥ ART ꯂꯥꯏꯌꯦꯡ ꯑꯃꯁꯨꯡ ꯑꯉꯥꯡ ꯑꯗꯨꯗꯥ ꯄꯣꯀꯄꯥ ꯃꯇꯨꯡꯗꯥ ꯑꯈꯟꯅꯕꯥ ꯍꯤꯗꯥꯛ-ꯂꯥꯡꯊꯀꯁꯤꯡ ꯄꯤꯕꯅꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯃꯃꯥꯗꯒꯤ ꯑꯉꯥꯡꯗꯥ ꯁꯟꯗꯣꯔꯀꯄꯒꯤ ꯔꯤꯁ꯭ꯛ ꯑꯁꯤ 1%ꯗꯒꯤ ꯇꯥꯅꯥ ꯍꯟꯊꯍꯅꯕꯥ ꯉꯝꯃꯤ꯫
ARTꯅꯥ ꯍꯀꯆꯥꯡꯗꯒꯤ HIV ꯃꯄꯨꯡꯐꯥꯅꯥ ꯐꯍꯅꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ? ▼
ꯅꯠꯇꯦ, ꯍꯧꯖꯤꯛꯀꯤ ꯑꯣꯏꯅꯥ ꯃꯥꯂꯦꯃꯗꯥ HIVꯒꯤ ꯍꯤꯗꯥꯛ ꯑꯃꯠꯇꯥ ꯂꯩꯇꯦ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ART ꯗ꯭ꯔꯒꯁꯤꯡꯅꯥ ꯚꯥꯏꯔꯁ ꯑꯁꯤ ꯍꯀꯆꯥꯡꯗꯥ ꯏꯅꯑꯦꯛꯇꯤꯚ ꯑꯣꯏꯅꯥ ꯊꯝꯕꯥ ꯉꯝꯃꯤ ꯑꯃꯁꯨꯡ ꯃꯤꯑꯣꯏꯕꯕꯨ ꯅꯣꯔꯃꯦꯜ, ꯍꯀꯁꯦꯜ ꯐꯕꯥ ꯄꯨꯟꯁꯤ ꯑꯃꯥ ꯍꯤꯡꯍꯅꯕꯥ ꯉꯝꯃꯤ꯫
💬 Comments (0)
No comments yet. Be the first to share your thoughts here.
Add Your Comment